A Phase II Study of R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase II Study of R-CHOP [rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 01 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 01 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top